Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of LYPD1 in diagnosis, treatment, prognosis and recurrence prediction of hepatocellular carcinoma

A technology in liver cancer and samples, applied in the field of biomedicine, can solve the problems of limited and immature liver cancer markers

Active Publication Date: 2020-11-03
SUN YAT SEN UNIV CANCER CENT
View PDF6 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, only alpha-fetoprotein (AFP) is the molecular diagnostic marker commonly used clinically for liver cancer. Although serum AFP can change significantly in the early stages of liver cancer, it cannot provide guidance for the treatment of liver cancer and effectively predict tumor progression. relapse
To date, global liver cancer markers for predicting early recurrence and poor prognosis are immature, and there are limited tools to guide treatment and understand tumor progression for newly diagnosed patients with advanced liver cancer

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of LYPD1 in diagnosis, treatment, prognosis and recurrence prediction of hepatocellular carcinoma
  • Application of LYPD1 in diagnosis, treatment, prognosis and recurrence prediction of hepatocellular carcinoma
  • Application of LYPD1 in diagnosis, treatment, prognosis and recurrence prediction of hepatocellular carcinoma

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0029] By analyzing the TCGA database, the inventor found that the gene LYPD1 was significantly highly expressed in liver cancer tissue compared with normal liver tissue, and was closely related to cancer stage. The specific operation is as follows:

[0030] 1. TCGA database analysis

[0031] Methods: 419 samples (369 cases of liver cancer tissue and 50 cases of normal liver tissue) in the TCGA database were analyzed, and the expression level of LYPD1 in each sample was calculated by log 2 (TPM+1) is displayed in the form of points in the figure after normalization, and the box plots formed by different groups of points are distinguished by left and right, the box plot of liver cancer tissue is on the left, and the box plot of normal tissue is on the right . The upper and lower edges of each box plot represent the maximum and minimum values ​​of LYPD1 expression in the corresponding group, and the upper and lower sides of the box represent the upper and lower quartiles of LYP...

Embodiment 2

[0040] The inventors found that in patients with advanced liver cancer treated with hepatic arterial infusion of FOLFOX, the expression level of LYPD1 significantly affects the curative effect of treatment, and the overall evaluation of treatment response in patients with high expression level of LYPD1 is significantly better than that in patients with low expression level of LYPD1.

[0041] Methods: A retrospective study was used to analyze the clinical data of 40 patients with advanced hepatocellular carcinoma who were admitted to the Department of Hepatobiliary and Pancreatic Surgery of Sun Yat-sen University Cancer Center and received HAIC from February 2016 to April 2018. Tissue RNA was extracted from the puncture specimens of these patients before HAIC treatment, and RNA sequencing was performed. According to the tumor response after HAIC treatment (RECIST standard), they were divided into a tumor progression (PD) group and a non-tumor progression (PR) group, and the diff...

Embodiment 3

[0043] Example 3: The correlation between the expression level of LYPD1 and the prognosis of patients with advanced liver cancer using the hepatic artery infusion FOLFOX regimen

[0044] 1. The expression level of LYPD1 was significantly positively correlated with the overall survival of patients with advanced liver cancer treated with hepatic arterial infusion of FOLFOX regimen.

[0045] Methods: Using the method of retrospective study, 40 patients were divided into two groups with high expression of LYPD1 and low expression of LYPD1, taking the median of LYPD1 expression as the boundary. All statistical analyzes were processed with SPSS25.0 statistical software. The Kaplan-Meier method was used to draw the survival analysis curve, and the log-rank test was used to detect the statistical significance. A test coefficient of P<0.05 was considered statistically significant. SPSS statistical software was used to analyze the relationship between the expression of LYPD1 and the o...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to an application of a molecular marker LYPD1 gene in diagnosis of liver cancer, liver cancer differentiation and liver cancer prognosis, which comprises the following steps: selecting sequencing data and clinical information of a liver cancer patient from a TCGA database, selecting, classifying and analyzing the data to obtain a differential expression gene related to livercancer differentiation, and carrying out clinical experiment verification. Results show that the expression of the LYPD1 gene is highly related to liver cancer differentiation and liver cancer prognosis. The molecular marker closely related to liver cancer prognosis provided by the invention can be used for dynamically monitoring FOLFOX scheme treatment prognosis accepted by liver cancer patients,and has important clinical significance and application prospects.

Description

technical field [0001] The invention belongs to the field of biomedicine and relates to the application of a biomarker in the diagnosis, treatment, prognosis and recurrence prediction of hepatocellular carcinoma, and the marker is LYPD1. Background technique [0002] In China, hepatocellular carcinoma (hereinafter referred to as liver cancer) ranks fourth in the incidence of malignant tumors and the second in mortality. The traditional treatment methods for liver cancer mainly include surgical resection, radiofrequency ablation, liver transplantation and other local treatments, as well as interventional transarterial chemoembolization (hereinafter referred to as TACE), transhepatic arterial infusion chemotherapy (hereinafter referred to as HAIC), biological immunotherapy and other means. Each of these treatments has its own strengths, and each has certain indications and limitations. Most of the liver cancer patients in China are diagnosed at the advanced stage when the tum...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C12Q1/6886G01N33/574A61K45/00A61P35/00
CPCC12Q1/6886G01N33/57438A61K45/00A61P35/00C12Q2600/158C12Q2600/118C12Q2600/112
Inventor 赖志城简沛恩陈海龙石明
Owner SUN YAT SEN UNIV CANCER CENT
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com